AHRQ NSAID final report
Executive Summary
Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...